FORA Capital LLC Takes $436,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

FORA Capital LLC purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 24,004 shares of the life sciences company’s stock, valued at approximately $436,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IART. CWM LLC increased its position in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares in the last quarter. Blue Trust Inc. boosted its stake in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Integra LifeSciences by 1.1% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock worth $1,764,000 after purchasing an additional 551 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Integra LifeSciences by 7.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company’s stock worth $421,000 after purchasing an additional 1,010 shares during the last quarter. Finally, KBC Group NV lifted its holdings in shares of Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 0.2 %

Shares of IART stock opened at $24.58 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a market cap of $1.90 billion, a P/E ratio of -273.08, a PEG ratio of 0.83 and a beta of 1.08. The company has a 50 day moving average of $20.63 and a 200-day moving average of $24.01. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the business posted $0.76 earnings per share. Sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

IART has been the subject of several recent research reports. Citigroup upped their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America reduced their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Finally, Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and an average target price of $24.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.